Chemomab Therapeutics (CMMB) Tops Q4 EPS by 8c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of ($0.02), $0.08 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49